Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Innovent Biologics, Inc. (1801.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
36.150+3.850 (+11.92%)
At close: 04:08PM HKT
Advertisement
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.
Currency in HKD

Valuation Measures4

Yahoo Finance Plus required to access annual data
Annual
Quarterly
Yahoo Finance Plus required to access monthly data
Monthly
Subscribe to Yahoo Finance Plus Essential to download historical data
 
As of Date: 6/25/2022
Current
Market Cap (intraday)
N/A
Enterprise Value
N/A
Trailing P/E
N/A
Forward P/E
N/A
PEG Ratio (5 yr expected)
N/A
Price/Sales (ttm)
N/A
Price/Book (mrq)
N/A
Enterprise Value/Revenue
N/A
Enterprise Value/EBITDA
N/A

Trading Information

Stock Price History

Beta (5Y Monthly) -0.01
52-Week Change 3N/A
S&P500 52-Week Change 3N/A
52 Week High 394.750
52 Week Low 318.060
50-Day Moving Average 324.548
200-Day Moving Average 345.771

Share Statistics

Avg Vol (3 month) 310.54M
Avg Vol (10 day) 314.78M
Shares Outstanding 51.46B
Implied Shares Outstanding 6N/A
Float 81.25B
% Held by Insiders 17.49%
% Held by Institutions 144.09%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in CNY.

Fiscal Year

Fiscal Year Ends Dec 31, 2021
Most Recent Quarter (mrq)Dec 31, 2021

Profitability

Profit Margin -73.50%
Operating Margin (ttm)-72.90%

Management Effectiveness

Return on Assets (ttm)-13.86%
Return on Equity (ttm)-32.84%

Income Statement

Revenue (ttm)4.27B
Revenue Per Share (ttm)2.93
Quarterly Revenue Growth (yoy)-18.60%
Gross Profit (ttm)2.98B
EBITDA -2.95B
Net Income Avi to Common (ttm)-3.14B
Diluted EPS (ttm)N/A
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)9.02B
Total Cash Per Share (mrq)6.17
Total Debt (mrq)2.5B
Total Debt/Equity (mrq)24.17
Current Ratio (mrq)3.79
Book Value Per Share (mrq)8.16

Cash Flow Statement

Operating Cash Flow (ttm)-2.02B
Levered Free Cash Flow (ttm)-2.46B
Advertisement
Advertisement